CSIMarket Company Name, Ticker, Suppliers, else..


Rigel Pharmaceuticals Inc  (NASDAQ: RIGL)
Other Ticker:  
 

Rigel Pharmaceuticals Inc

RIGL's Fundamental analysis



Looking into Rigel Pharmaceuticals Inc growth rates, revenue grew by 80.58 % in the first quarter of 2025 from the same quarter a year ago.

Major Pharmaceutical Preparations industry recorded growth of revenues by 4.5 %

Rigel Pharmaceuticals Inc realized net income compared to net loss a year ago in first quarter of 2025

• More on RIGL's Growth


Rigel Pharmaceuticals Inc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Rigel Pharmaceuticals Inc PEG ratio is at -0.05 Company is currently trading with Price to Cash flow multiple of 18.45 in trailing twelve-month period.
Company
9.98
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 1.84.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.49.


• More on RIGL's Valuation
 
 Total Debt (Millions $) 60
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 1,504,274
 Net Income/Employee (TTM) $ 275,393
 Receivable Turnover (TTM) 5.69
 Tangible Book Value (Per Share $) -0.44

Rigel Pharmaceuticals Inc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Rigel Pharmaceuticals Inc PEG ratio is at -0.05 Company is currently trading with Price to Cash flow multiple of 18.45 in trailing twelve-month period.
Company
9.98
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 1.84.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.49.

Rigel Pharmaceuticals Inc Price to Book Ratio is at 20.08 lower than Industry Avg. of 35.2. and higher than S&P 500 Avg. of 0.01

• More on RIGL's Valuation

•  Market Capitalization (Millions $) 373
•  Shares Outstanding (Millions) 18
•  Employees 135
•  Revenues (TTM) (Millions $) 203
•  Net Income (TTM) (Millions $) 37
•  Cash Flow (TTM) (Millions $) 20
•  Capital Exp. (TTM) (Millions $) -
•  Total Debt (Millions $) 60
•  Dividend TTM ($) 0 $
•  Dividend Yield TTM (%) -
•  Revenue/Employee (TTM) $ 1,504,274
•  Net Income/Employee(TTM) $ 275,393
•  Receivable Turnover Ratio (TTM) 5.69
•  Tangible Book Value (Per Share $) -0.44

•  Market Capitalization (Millions $) 373
•  Shares Outstanding (Millions) 18
•  Employees 135
•  Revenues (TTM) (Millions $) 203
•  Net Income (TTM) (Millions $) 37
•  Cash Flow (TTM) (Millions $) 20
•  Capital Exp. (TTM) (Millions $) -


    RIGL's Profitability Comparisons
Rigel Pharmaceuticals Inc faced margin deterioration, primarily through cost pressure. Operating Margin fell in first quarter of 2025 to 23.95 % from 28.92 % in IV. Quarter.

Rigel Pharmaceuticals Inc net profit margin of 21.46 % is currently ranking no. 29 in Major Pharmaceutical Preparations industry, ranking no. 51 in Healthcare sector and number 623 in S&P 500.


Profitability by Segment
Total 21.46 %



  Ratio
•   Capital Ratio (MRQ) 2.2
•  Total Debt to Equity (MRQ) 3.22
•  Tangible Leverage Ratio (MRQ) -
•  Asset Turnover Ratio (TTM) 1.34
•  Inventory Turnover Ratio (TTM) 3.58



Rigel Pharmaceuticals Inc faced margin deterioration, primarily through cost pressure. Operating Margin fell in first quarter of 2025 to 23.95 % from 28.92 % in IV. Quarter.

Rigel Pharmaceuticals Inc net profit margin of 21.46 % is currently ranking no. 29 in Major Pharmaceutical Preparations industry, ranking no. 51 in Healthcare sector and number 623 in S&P 500.

• More on RIGL's Key Ratios





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com